Crinetics Pharmaceuticals Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Crinetics Pharmaceuticals stock.
View analyst ratings for Crinetics Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Crinetics Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Crinetics Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Crinetics Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, March 8th 2021.
View our earnings forecast for Crinetics Pharmaceuticals.

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) issued its quarterly earnings data on Wednesday, November, 11th. The company reported ($0.56) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.53) by $0.03.
View Crinetics Pharmaceuticals' earnings history.

Crinetics Pharmaceuticals' stock was trading at $15.50 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CRNX stock has decreased by 2.5% and is now trading at $15.11.
View which stocks have been most impacted by COVID-19.

3 brokers have issued 12 month price targets for Crinetics Pharmaceuticals' shares. Their forecasts range from $30.00 to $42.00. On average, they expect Crinetics Pharmaceuticals' stock price to reach $36.00 in the next year. This suggests a possible upside of 138.3% from the stock's current price.
View analysts' price targets for Crinetics Pharmaceuticals or view top-rated stocks among Wall Street analysts.

2 employees have rated Crinetics Pharmaceuticals CEO R. Scott Struthers, Ph.D. on Glassdoor.com. R. Scott Struthers, Ph.D. has an approval rating of 100% among Crinetics Pharmaceuticals' employees. This puts R. Scott Struthers, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Crinetics Pharmaceuticals include Myovant Sciences (MYOV), Kura Oncology (KURA), Revance Therapeutics (RVNC), Madrigal Pharmaceuticals (MDGL), Harmony Biosciences (HRMY), Generation Bio (GBIO), Stoke Therapeutics (STOK), ImmunoGen (IMGN), NGM Biopharmaceuticals (NGM), Pandion Therapeutics (PAND), Seres Therapeutics (MCRB), Zentalis Pharmaceuticals (ZNTL), Aurinia Pharmaceuticals (AUPH), Ironwood Pharmaceuticals (IRWD) and Organogenesis (ORGO).
View all of CRNX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Crinetics Pharmaceuticals investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), G1 Therapeutics (GTHX), Kura Oncology (KURA), Otonomy (OTIC), Selecta Biosciences (SELB), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS) and Applied Genetic Technologies (AGTC).

(CRNX) raised $80 million in an IPO on Wednesday, July 18th 2018. The company issued 5,000,000 shares at $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray served as the underwriters for the IPO.

Crinetics Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRNX."

Crinetics Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.42%), Baker BROS. Advisors LP (1.87%), Northern Trust Corp (0.96%), Bank of New York Mellon Corp (0.83%), Charles Schwab Investment Management Inc. (0.46%) and Nuveen Asset Management LLC (0.42%). Company insiders that own Crinetics Pharmaceuticals stock include Matthew K Fust, Richard Scott Struthers, Ventures Iv LP 5Am, Vivo Capital Fund Viii, LP and Vivo Capital Viii, Llc.
View institutional ownership trends for Crinetics Pharmaceuticals.

CRNX stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Victory Capital Management Inc., Northern Trust Corp, Price T Rowe Associates Inc. MD, State of Wisconsin Investment Board, and Barclays PLC. Company insiders that have sold Crinetics Pharmaceuticals company stock in the last year include Richard Scott Struthers, and Vivo Capital Viii, Llc.
View insider buying and selling activity for Crinetics Pharmaceuticals or view top insider-selling stocks.

CRNX stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Baker BROS. Advisors LP, Bank of New York Mellon Corp, JPMorgan Chase & Co., Renaissance Technologies LLC, Dimensional Fund Advisors LP, Credit Suisse AG, and Squarepoint Ops LLC.
View insider buying and selling activity for Crinetics Pharmaceuticals or or view top insider-buying stocks.

Shares of CRNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CRNX stock can currently be purchased for approximately $15.11.

Crinetics Pharmaceuticals has a market capitalization of $497.45 million and generates $1.19 million in revenue each year. The company earns $-50,420,000.00 in net income (profit) each year or ($2.09) on an earnings per share basis.

Crinetics Pharmaceuticals employs 68 workers across the globe.

The official website for Crinetics Pharmaceuticals is www.crinetics.com.

Crinetics Pharmaceuticals is headquartered at 10222 Barnes Canyon Road Building #2, San Diego CA, 92121.

Crinetics Pharmaceuticals' mailing address is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. The company can be reached via phone at 858-450-6464 or via email at [email protected]